Myriad Genetics, Inc., a molecular diagnostic company, focuses on developing and marketing novel predictive medicine, personalized medicine, and prognostic medicine tests worldwide. The company has market cap of $2.30 billion. The firm offers molecular diagnostic tests, including myRisk Hereditary Cancer, a DNA sequencing test for hereditary cancers; BRACAnalysis, a DNA sequencing test to assess the risk of developing breast and ovarian cancer; BART, a DNA sequencing test for hereditary breast and ovarian cancer; BRACAnalysis CDx, a DNA sequencing test for use as a companion diagnostic with the platinum based chemotherapy agents and poly ADP ribose inhibitor Lynparza; and Tumor BRACAnalysis CDx, a DNA sequencing test that is designed to be utilized to predict response to DNA damaging agents. It has a 17.68 P/E ratio. It also provides COLARIS, a DNA sequencing test for colorectal and uterine cancer; COLARIS AP, a DNA sequencing test for colorectal cancer; Vectra DA, a protein quantification test for assessing the disease activity of rheumatoid arthritis; Prolaris, a RNA expression test for assessing the aggressiveness of prostate cancer; and EndoPredict, a RNA expression test for assessing the aggressiveness of breast cancer.
Analysts expect Apricus Biosciences, Inc. (NASDAQ:APRI) to report $-0.13 EPS on March, 12.They anticipate $0.09 EPS change or 225.00% from last quarter’s $-0.04 EPS. After having $-0.30 EPS previously, Apricus Biosciences, Inc.’s analysts see -56.67% EPS growth. The stock decreased 61.77% or $1.9706 during the last trading session, reaching $1.2194. About 12.58 million shares traded or 1923.54% up from the average. Apricus Biosciences, Inc. (NASDAQ:APRI) has declined 71.78% since February 16, 2017 and is downtrending. It has underperformed by 88.48% the S&P500.
Consonance Capital Management Lp holds 7.9% of its portfolio in Myriad Genetics, Inc. for 1.97 million shares. Tieton Capital Management Llc owns 251,143 shares or 7.81% of their US portfolio. Moreover, Camber Capital Management Llc has 4.59% invested in the company for 2.00 million shares. The Pennsylvania-based S&T Bank Pa has invested 3.15% in the stock. Millrace Asset Group Inc., a Pennsylvania-based fund reported 32,738 shares.
The stock decreased 1.29% or $0.43 during the last trading session, reaching $32.95. About 174,694 shares traded. Myriad Genetics, Inc. (MYGN) has declined 37.47% since February 16, 2017 and is downtrending. It has underperformed by 54.17% the S&P500.
Since January 1, 0001, it had 0 insider purchases, and 8 sales for $6.39 million activity.
Ratings analysis reveals 0 of Myriad Genetics’s analysts are positive. Out of 2 Wall Street analysts rating Myriad Genetics, 0 give it “Buy”, 2 “Sell” rating, while 0 recommend “Hold”. MYGN was included in 2 notes of analysts from October 10, 2016. The stock has “Sell” rating by Deutsche Bank on Wednesday, January 18. Ladenburg Thalmann downgraded the shares of MYGN in report on Monday, October 10 to “Sell” rating.
Among 6 analysts covering Apricus Bioscience Inc (NASDAQ:APRI), 3 have Buy rating, 0 Sell and 3 Hold. Therefore 50% are positive. Apricus Bioscience Inc had 11 analyst reports since August 6, 2015 according to SRatingsIntel. Roth Capital downgraded the shares of APRI in report on Friday, November 6 to “Neutral” rating. H.C. Wainwright maintained the stock with “Buy” rating in Wednesday, August 30 report. The stock has “Buy” rating by H.C. Wainwright on Tuesday, January 16. The firm has “Buy” rating given on Friday, November 3 by H.C. Wainwright. The company was maintained on Thursday, August 3 by H.C. Wainwright. Ascendiant Capital Markets initiated it with “Buy” rating and $2.50 target in Thursday, August 13 report. FBR Capital maintained Apricus Biosciences, Inc. (NASDAQ:APRI) on Friday, November 6 with “Outperform” rating. The company was downgraded on Wednesday, December 9 by Sterne Agee CRT. The firm earned “Buy” rating on Tuesday, September 5 by H.C. Wainwright. The rating was downgraded by TH Capital to “Neutral” on Friday, November 6.